Physicians' attitudes toward post-MI aspirin prophylaxis: Findings from an online questionnaire in Europe and Latin America

Postgraduate Medicine

Volumn 121, Issue 6, 2009, Pages 44-53

  Zaninelli, Augusto ^a   Kaufholz, Carola ^b   Schwappach, David ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Bayer Consumer Care AG   (Switzerland)

^c Institut fur Sucht und Gesundheitsforschung Zurich   (Switzerland)

Author keywords

ACT study; Aspirin; Compliance; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL PRACTICE; DRUG DOSE REGIMEN; EUROPE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH SURVEY; HEART INFARCTION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MONOTHERAPY; NORMAL HUMAN; ONLINE SYSTEM; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PHYSICIAN ATTITUDE; PROPHYLAXIS; QUESTIONNAIRE; RECURRENT DISEASE; SOUTH AND CENTRAL AMERICA; TABLET; CLINICAL TRIAL; HEALTH CARE SURVEY; MIDDLE AGED; MULTICENTER STUDY; PRACTICE GUIDELINE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; EUROPE; FEMALE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; LATIN AMERICA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; RECURRENCE;

EID: 73949152621     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.11.2070     Document Type: Article

References (27)

1. American Stroke Association American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. 2005:1-60.
2. Adabag AS, Therneau TM, Gersh BJ, et al. Sudden death after myocardial infarction. JAMA. 2008;300(17):2022-2029.
3. Tribouilloy C, Buiciuc O, Rusinaru D, Malaquin D, Lévy F, Peltier M. Long-term outcome after a first episode of heart failure. A prospective 7-year study [published online ahead of print December 17, 2008]. Int J Cardiol.
4. Becker RC, Meade TW, Berger PB, et al. American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):776S-814S.
5. Graham I, Atar D, Borch-Johnsen K, et al. European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Journal of Cardiovasc Prev Rehabil. 2007;14(suppl 2):E1-E40.
6. US Preventive Services Task Force, Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396-404.
7. Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860.
8. The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group. Circulation. 1980;62(6 pt 2):V79-V84.
9. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ. 1998;316(7141):1337-1343.
10. Breddin K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis. 1980;9(6):325-344.
11. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J. 1974;1(5905):436-440.
12. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979;2(8156-8157):1313-1315.
13. Elwood PC, Williams WO. A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. J R Coll Gen Pract. 1979;29(204):413-416.
14. Hennekens CH, Schneider WR. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Expert Rev Cardiovasc Ther. 2008;6(1):95-107.
15. Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group. Circulation. 1980;62(3):449-461.
16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
17. Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med. 2003;163(12):1430-1439.
18. Abdallah MH, Arnaout S, Karrowni W, Dakik HA. The management of acute myocardial infarction in developing countries. Int J Cardiol. 2006;111(2):189-194.
19. Reaume KT, Regal RE, Dorsch MP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann Pharmacother. 2008;42(4):550-557.
20. Toth PP. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Postgrad Med. 2009;121(1):59-72.
21. van den Bergh PJ, Kievit PC, Brouwer MA, Aengevaeren WR, Veen G, Verheugt FW. Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction to reocclusion to improved long-term clinical outcome. Am Heart J. 2009;157(3):532-540.
22. Sacco RL, Adams R, Albers G, et al. American Heart Association/American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113(10):e409-e449.
23. Cotter G, Shermesh E, Zehavi M, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004;147(2):293-300.
24. Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. Circulation. 2008;117(10):1261-1268.
25. Moran A, Goldman L. Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction - but at what cost to Medicare? Nat Clin Pract Cardiovasc Med. 2008;5(10):606-607.
26. Choudhry NK, Brennan T, Toscano M, et al. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008;156(1):31-36.
27. Roth A, Malov N, Steinberg DM, et al. Telemedicine for post-myocardial infarction patients: an observational study. Telemed J E Health. 2009;15(1):24-30.